Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: SBR004
MIFTS: 44

Seborrheic Dermatitis

Categories: Skin diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Seborrheic Dermatitis

About this section

MalaCards integrated aliases for Seborrheic Dermatitis:

Name: Seborrheic Dermatitis 12 36 29 54 15 17 70
Seborrhoeic Dermatitis 12 32
Dermatitis, Seborrheic 44
Seborrhoeic Eczema 12
Skin Seborrheic 12
Seborrhea 12

Classifications:

MalaCards categories:
Anatomical: Skin diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:8741
KEGG 36 H01652
ICD9CM 34 690.1
MeSH 44 D012628
NCIt 50 C111888
SNOMED-CT 67 156328004
ICD10 32 L21 L21.9
UMLS 70 C0036508
Sources

Summaries for Seborrheic Dermatitis

About this section
KEGG : 36 Seborrheic dermatitis (SD) is a common inflammatory dermatological disorder. The characteristic symptoms include scaling, erythema, and itching, which occur most often on the scalp, face, chest, back, axilla, and groin. Its incidence peaks during three age periods: in the first three months of life, during puberty, and in adulthood with an apex at 40 to 60 years of age. The cause of SD is unknown and the disease seems to be multifactorial. Malassezia yeasts are considered to play an important role. They cause an inflammatory reaction that seems to be mediated by free fatty acids, released from sebaceous triglycerides by fungal enzymes such as lipases. The lipid layer of Malassezia can also modulate pro-inflammatory cytokine production by keratinocytes. Although it can be associated with human immunodeficiency virus infection and neurologic disease (e.g., cerebrovascular event, Parkinson disease), SD typically occurs in healthy persons. Its prevalence is 1% to 3% in the general population and 34% to 83% in immunocompromised persons. Topical antifungal agents are the first-line therapy for acute and long-term treatment of SD of the face and body. Treatment includes over-the-counter shampoos and topical antifungals, calcineurin inhibitors, and corticosteroids.

MalaCards based summary : Seborrheic Dermatitis, also known as seborrhoeic dermatitis, is related to keratosis, seborrheic and dermatitis. An important gene associated with Seborrheic Dermatitis is BTD (Biotinidase), and among its related pathways/superpathways are Keratinization and Tight junction. The drugs Isotretinoin and Clotrimazole have been mentioned in the context of this disorder. Affiliated tissues include skin, tongue and eye.

Disease Ontology : 12 A dermatitis that is an inflammatory skin condition resulting in flaky, white to yellowish scales on oily areas such as the scalp or inside the ear, which is caused due to a combination of an over production of skin oil and irritation from a yeast Malassezia furfur. The symptoms include itching, skin lesions and scales, redness, plaques and hair loss.

Wikipedia : 73 Seborrhoeic dermatitis, also known as seborrhoea, is a long-term skin disorder. Symptoms include red,... more...

Sources

Related Diseases for Seborrheic Dermatitis

About this section

Diseases in the Seborrheic Dermatitis family:

Seborrheic Infantile Dermatitis

Diseases related to Seborrheic Dermatitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 233)
# Related Disease Score Top Affiliating Genes
1 keratosis, seborrheic 31.2 CD1E CD1C CD1B CD1A
2 dermatitis 30.7 ZNF750 SPINK5 FLG DSG1 DEFB4A CD4
3 acne 30.6 SHBG FLG DEFB4A
4 dermatophytosis 30.4 DEFB4A CD4 CCR6
5 dermatitis, atopic 30.4 SPINK5 FLG DEFB4A CD4 CCR6
6 contact dermatitis 30.1 FLG DEFB4A CD4 CCR6
7 hair disease 30.0 SHBG DSG1 CD4 CCR6
8 pityriasis rosea 30.0 CD1E CD1A
9 mite infestation 30.0 FLG CD4 CD1B CD1A
10 skin sarcoidosis 29.9 CD4 CD1C CD1B
11 tinea corporis 29.8 SPINK5 FLG DEFB4A
12 oral candidiasis 29.7 DEFB4A CD4 CCR6
13 lichen planus 29.7 FLG DSG1 DEFB4A CD1A
14 skin disease 29.5 SPINK5 FLG DSG1 DEFB4A CD4 CD1C
15 granuloma annulare 29.5 CD4 CD1E CD1C CD1B CD1A
16 folliculitis 29.1 DEFB4A CD4 CD1E CD1C CD1B CD1A
17 disease by infectious agent 28.9 DEFB4A CD4 CD207 CD1C CD1A CCR6
18 seborrheic infantile dermatitis 11.6
19 seborrhea-like dermatitis with psoriasiform elements 11.6
20 garret tripp syndrome 11.2
21 blepharitis 11.2
22 hyperandrogenism 10.9
23 pustulosis of palm and sole 10.6
24 psoriasis 10.6
25 rosacea 10.5
26 pityriasis versicolor 10.5
27 exanthem 10.4
28 acquired immunodeficiency syndrome 10.4
29 suppurative lymphadenitis 10.3 CD4 CCR6
30 herpes simplex virus keratitis 10.3 CD4 CCR6
31 transient arthritis 10.3 FLG CD4
32 mikulicz disease 10.3 CD4 CCR6
33 chancroid 10.3 CD4 CCR6
34 marasmus 10.3 SHBG CD4
35 anti-basement membrane glomerulonephritis 10.3 CD4 CCR6
36 esophageal candidiasis 10.3 CD4 CCR6
37 alk+ histiocytosis 10.3 CD207 CD1A
38 nut allergy 10.3 FLG CCR6
39 acquired hyperkeratosis 10.3 SPINK5 DSG1
40 facial dermatosis 10.3
41 subcutaneous mycosis 10.3 CD4 CCR6
42 spinal cord disease 10.3 CD4 CCR6 BTD
43 urethral syndrome 10.2 SHBG CD4 CCR6
44 legume allergy 10.2 FLG CD4 CCR6
45 fruit allergy 10.2 FLG CD4 CCR6
46 predominantly cortical thymoma 10.2 CD1E CD1A
47 thyroid gland disease 10.2 SHBG CD4 CCR6
48 nasal cavity disease 10.2 FLG CD4 CCR6
49 tolosa-hunt syndrome 10.2 CD1E CD1A
50 skin atrophy 10.2

Graphical network of the top 20 diseases related to Seborrheic Dermatitis:



Diseases related to Seborrheic Dermatitis
Sources

Symptoms & Phenotypes for Seborrheic Dermatitis

About this section
Sources

Drugs & Therapeutics for Seborrheic Dermatitis

About this section

Drugs for Seborrheic Dermatitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 66)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Isotretinoin Approved Phase 4 4759-48-2 5282379 5538
2
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
3
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
4
Ketoconazole Approved, Investigational Phase 4 65277-42-1 47576
5
Tacrolimus Approved, Investigational Phase 4 104987-11-3 6473866 445643 439492
6 Salicylates Phase 4
7 Cyclooxygenase Inhibitors Phase 4
8 Keratolytic Agents Phase 4
9 Dermatologic Agents Phase 4
10 Anti-Infective Agents Phase 4
11 Antifungal Agents Phase 4
12 Immunosuppressive Agents Phase 4
13 Immunologic Factors Phase 4
14 Calcineurin Inhibitors Phase 4
15 Cytochrome P-450 CYP3A Inhibitors Phase 4
16 Cytochrome P-450 Enzyme Inhibitors Phase 4
17 Hormone Antagonists Phase 4
18 Hormones Phase 4
19 Emollients Phase 4
20 Anti-Inflammatory Agents Phase 4
21
Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
22
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
23
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
24
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
25
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
26
Betamethasone Approved, Vet_approved Phase 3 378-44-9 9782
27
Ciclopirox Approved, Investigational Phase 3 29342-05-0 2749
28
Clobetasol Approved, Experimental, Investigational Phase 3 25122-41-2, 25122-46-7 32798 5311051
29
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7
30 Anti-Asthmatic Agents Phase 3
31 Respiratory System Agents Phase 3
32 Gastrointestinal Agents Phase 3
33 Methylprednisolone Acetate Phase 3
34 Neuroprotective Agents Phase 3
35 Antiemetics Phase 3
36 Antineoplastic Agents, Hormonal Phase 3
37 Betamethasone Valerate Phase 3 2152-44-5
38 Betamethasone benzoate Phase 3
39 Betamethasone-17,21-dipropionate Phase 3
40 Betamethasone sodium phosphate Phase 3
41 Protective Agents Phase 3
42 glucocorticoids Phase 3
43
Pimecrolimus Approved, Investigational Phase 2 137071-32-0 6447131 17753757
44
Azelaic acid Approved Phase 2 123-99-9 2266
45 Analgesics, Non-Narcotic Phase 2
46 Antirheumatic Agents Phase 2
47 Analgesics Phase 2
48 Anti-Inflammatory Agents, Non-Steroidal Phase 2
49 Pharmaceutical Solutions Phase 2
50 Epidiolex Phase 2

Interventional clinical trials:

(show all 34)
# Name Status NCT ID Phase Drugs
1 Clinical, Laboratorial and Quality of Life Trial to Evaluate the Efficacy and Safety of Low-dose Oral Isotretinoin for Seborrhea. Unknown status NCT01139749 Phase 4 oral isotretinoin;salicylic acid and ciclopirox olamine
2 A PHASE 4, OPEN-LABEL STUDY TO ASSESS THE LONG-TERM SAFETY OF EXTINA (KETOCONAZOLE) FOAM, 2% IN THE TREATMENT OF SEBORRHEIC DERMATITIS Completed NCT00703846 Phase 4 Ketoconazole
3 A Double Blind, Placebo-Controlled, Pilot Study to Estimate the Efficacy and Tolerability of Twice Daily Promiseb Topical Cream in Pediatric Subjects With Cradle Cap (Seborrheic Dermatitis) Completed NCT01214434 Phase 4
4 Phase 4 Study of Proactive Treatment of Tacrolimus Ointment for Adult Facial Seborrheic Dermatitis Completed NCT01591070 Phase 4 Tacrolimus;Tacrolimus
5 A Proof of Concept Clinical Trial Evaluating the Safety and Efficacy of Eucrisa (Crisaborole) in Patients With Seborrheic Dermatitis Recruiting NCT03567980 Phase 4 Crisaborole
6 Comparative Evaluation of the Efficacy and Tolerability of Prednisolone Acetate 0.5% Cream Versus Betamethasone Valerate 0.1% Cream in the Treatment of Pediatric and Adult Dermatosis Unknown status NCT01011621 Phase 3 0.5% prednisolone acetate cream;0.1% betamethasone valerate cream
7 A Multicenter, Randomised Double Blind, Placebo Controlled Study of Efficacy, Safety and Tolerability of Two Topical K40 Formulations in Adults With Seborrhoeic Dermatitis (SD) of the Scalp. Completed NCT01137630 Phase 2, Phase 3 K40a;K40b;Placebo
8 A Multicenter, Randomised, Double Blind, Placebo-controlled Study of Efficacy, Safety, and Tolerability of Kaprolac® K301 for the Treatment of Seborrhoeic Eczema (SE) of the Scalp Completed NCT01137331 Phase 3 K301;Placebo
9 Efficacy and Safety of ASF 1057 Cream 0.5% in the Treatment of Seborrhoeic Dermatitis: A Phase III Randomised, Double-Blind, Vehicle and Placebo Controlled, Parallel Groups, Multi-Centre Trial. Completed NCT00565279 Phase 3 ASF1057;ASF1057
10 Phase 3 : Tacrolimus Ointment Interest (PROTOPIC ®) in the Maintenance Treatment of Severe Seborrheic Dermatitis on Adult Face Completed NCT02004860 Phase 3 Protopic (R);Mycoster (R)
11 Efficacy and Safety of Clobetasol Propionate Shampoo 0.05% Used in Association With an Antifungal Shampoo in the Treatment of Moderate to Severe Scalp Seborrheic Dermatitis Completed NCT00862654 Phase 3 clobetasol propionate shampoo (4/week) - ketoconazole shampoo (2/week);clobetasol propionate shampoo (2/week) - ketoconazole shampoo (2/week);clobetasol propionate shampoo (2/week);ketoconazole shampoo (2/week)
12 A Phase 2, Randomized, Vehicle and Ketoconazole-Controlled, Evaluator-Blinded, Study to Explore the Efficacy, Pharmacodynamics and Safety of Omiganan 1.75% Topical Gel BID in Patients With Mild to Moderate Facial Seborrheic Dermatitis Unknown status NCT03688971 Phase 2 Omiganan;Ketoconazole;Placebo
13 A 4 Week Randomized Double-Blind Parallel Group Active Comparator Controlled Study of Elidel for the Treatment of Seborrheic Dermatitis Completed NCT00403559 Phase 2 Elidel
14 The Role of Topically Dissolved Oxygen (TDO) to Ameliorate Signs of Photodamage in Individuals With Multiple Skin Conditions A Double-Blind, Placebo Controlled Comparative Trial Completed NCT00991198 Phase 2 Topical oxygen;Topical oxygen;placebo
15 A Randomized, Double-blind, Single Center, Investigator-initiated Clinical Study to Evaluate the Safety and Efficacy of PAC-14028 Cream in Subjects With Mild to Moderate Seborrheic Dermatitis of the Face Completed NCT02749383 Phase 2 PAC-14028 cream 0.3%;PAC-14028 cream 1.0%;PAC-14028 cream vehicle
16 A Double-Blind, Randomized, Vehicle-Controlled, Six-Week Exploratory Multicenter Pilot Study of the Efficacy and Safety of Azelaic Acid (AzA) 15% Gel in the Topical Treatment of Mild to Moderate Seborrheic Dermatitis of the Face Completed NCT00408330 Phase 2 Azelaic Acid 15% Gel;Inactive 15% gel base
17 A Phase 2b, 8-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-154 Foam 0.3% Administered QD in Subjects With Seborrheic Dermatitis Completed NCT04091646 Phase 2 ARQ-154 foam 0.3%
18 A Parallel-group, Vehicle-controlled, Randomized, Double-blind Study of the Efficacy and Safety of Product 49778 and Product 10156 in Subjects With Seborrheic Dermatitis Completed NCT01703793 Phase 2 Test Product 49778;Test Product 10156;Vehicle (placebo)
19 A 4-Week, Randomized, Double-Blind, Placebo-Controlled Proof-of-Concept Study to Evaluate the Potential of Topically Applied 0.75% (w/w) MTC896 Gel to Reduce Sebum Production on the Forehead of Healthy Male Volunteers Completed NCT01254162 Phase 2 MTC896 Gel
20 A Randomized, Double Blind, Placebo-controlled Parallel Study of Tolerability and Efficacy of Cannabidiol (CBD) on Motor Symptoms in Parkinson's Disease Recruiting NCT03582137 Phase 2 Cannabidiol
21 A Phase 2, Multicenter, Open-Label Study of the Long-Term Safety of ARQ-154 Foam 0.3% in Subjects With Seborrheic Dermatitis Recruiting NCT04445987 Phase 2 ARQ-154
22 Safety and Efficacy of a Topical Scalp Treatment for Dry Scalp Conditions in Children and Adults Recruiting NCT03830177 Phase 1, Phase 2 Natural Treatment
23 Double-blind, Randomized, Placebo Controlled Study Evaluating the Efficacy of Aerosal® in the Treatment of Inverse Psoriasis and Sebopsoriasis Withdrawn NCT01574872 Phase 2
24 Botulinum Toxin for Treatment of Seborrhic Dermatitis in Parkinsonian Patients Unknown status NCT00767546 Phase 1 Botulinum toxin
25 Petrolatum's Effect on Initial Symptoms of Nonscalp Seborrheic Dermatitis and Preventing Exacerbation Unknown status NCT01315951
26 Avaliação da eficácia de um Produto de Uso tópico Contendo Hidrocortisona no Tratamento de Dermatite seborréica na Face. Unknown status NCT01024374
27 Neurobiology of the Scalp in Seborrheic Dermatitis Completed NCT02349854
28 An Open-Label Study of the HairMax LaserComb(r) in the Treatment of Seborrheic Dermatitis of the Scalp. Completed NCT00830908
29 Safety and Efficacy of SEBORRHEAMEDIS Face Cream in Patients With Seborrheic Dermatitis Completed NCT02656368
30 Seborrheic Dermatitis of the Scalp in Populations Practicing Less Frequent Hair Washing: Ketoconazole 2% Foam Versus Ketoconazole 2% Shampoo Completed NCT01203189 ketoconazole 2% foam;ketoconazole 2% shampoo
31 Pilot Study for the Use of Photodynamic Therapy in the Treatment of Seborrheic Dermatitis Completed NCT03114111 aminolevulinic acid (ALA);Placebo
32 Comparison of Scalp Microbiota of the Patients With Psoriasis Vulgaris and Seborrheic Dermatitis Completed NCT03807453
33 Multicentric, Randomized, Double Blind Study Under Dermatological Control for Evaluation of the Antidandruff Maintenance Effect of One Shampoo (Reference 1144628 D) Versus Its Vehicle (Reference 1144781) During 8 Weeks After a Ketoconazole-based Antifungal Treatment During 4 Weeks in Adult Subjects (Male and Female) With Light to Moderate Seborrheic Dermatitis Recruiting NCT04057950
34 Using the SpiderMass(TM) for in Vivo and Real Time Mass Spectrometry Analysis of Subject's Epidermis Suffering From Chronic Inflammatory Dermatosis Compared to Control Groups Recruiting NCT04472546

Search NIH Clinical Center for Seborrheic Dermatitis

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Betamethasone
Betamethasone acetate
Betamethasone benzoate
betamethasone dipropionate
betamethasone sodium phosphate
Betamethasone valerate
BETAMETHASONE VALERATE PWDR
chloroxine
Coal Tar
Coal tar extract
Coal tar pitch volatiles
COAL TAR,COLLOIDAL
COAL TAR,REFINED
Colloid sulfur
Ketoconazole
Salicylic Acid
SALICYLIC ACID PWDR
selenium sulfide
Sulfacetamide
Sulfacetamide Sodium
Sulfur
SULFUR PWDR
SULFUR,COLLOIDAL
zinc pyrithione

Cochrane evidence based reviews: dermatitis, seborrheic

Sources

Genetic Tests for Seborrheic Dermatitis

About this section

Genetic tests related to Seborrheic Dermatitis:

# Genetic test Affiliating Genes
1 Seborrheic Dermatitis 29
Sources

Anatomical Context for Seborrheic Dermatitis

About this section

MalaCards organs/tissues related to Seborrheic Dermatitis:

40
Skin, Tongue, Eye, Spinal Cord, T Cells, Pituitary, Bone Marrow
Sources

Publications for Seborrheic Dermatitis

About this section

Articles related to Seborrheic Dermatitis:

(show top 50) (show all 1674)
# Title Authors PMID Year
1
The effect of isotretinoin on biotinidase activity. 61 54
10325581 1999
2
Infantile spasms as the initial symptom of biotinidase deficiency. 54 61
8283357 1994
3
Successful treatment with oral hydroxychloroquine of seborrhoeic dermatitis in a patient with AIDS. 61
33020968 2021
4
Scalp involvement in patients referred for patch testing: Retrospective cross-sectional analysis of North American Contact Dermatitis Group data, 1996 to 2016. 61
32822786 2021
5
Stem and progenitor cells in sebaceous gland development, homeostasis and pathologies. 61
33599012 2021
6
Sociodemographic characteristics and spectrum of Malassezia species in individuals with and without seborrhoeic dermatitis/dandruff: A comparison of residents of the urban and rural populations. 61
32556200 2021
7
Prevalence and cutaneous comorbidities of hidradenitis suppurativa in the German working population. 61
32322958 2021
8
A Novel Convolutional Neural Network for the Diagnosis and Classification of Rosacea: Usability Study. 61
33720027 2021
9
Inflammasome-mediated Inflammation by Malassezia in human keratinocytes: A comparative analysis with different strains. 61
33206994 2021
10
An updated review of the sebaceous gland and its role in health and diseases Part 2: Pathophysiological clinical disorders of sebaceous glands. 61
33571388 2021
11
Antagonistic Activity of Antimicrobial Metabolites Produced from Seaweed-Associated Bacillus amyloliquefaciens MTCC 10456 Against Malassezia spp. 61
33523421 2021
12
Increasing Access to Specialized Dermatology Care: A Retrospective Study Investigating Clinical Operation and Impact of a University-Affiliated Free Clinic. 61
33175327 2021
13
Potential role of the skin microbiota in Inflammatory skin diseases. 61
32562332 2021
14
Effect of zinc pyrithione shampoo treatment on skin commensal Malassezia. 61
32785575 2021
15
Phenols from Origanum dictamnus L. and Thymus vulgaris L. and their activity against Malassezia globosa carbonic anhydrase. 61
33533668 2021
16
Seborrheic dermatitis-distributed rash in dermatomyositis is associated with progressive interstitial lung disease. 61
33333153 2021
17
Parkinson's disease and skin. 61
33248395 2021
18
Serum Levels of 25-Hydroxyvitamin D in Patients with Seborrheic Dermatitis: A Case-Control Study. 61
33688341 2021
19
An updated review of the sebaceous gland and its role in health and diseases Part 1: Embryology, evolution, structure, and function of sebaceous glands. 61
33354858 2021
20
A simple technique to distinguish fibrosing alopecia in a pattern distribution from androgenetic alopecia and concomitant seborrheic dermatitis. 61
33440218 2021
21
Clinicopathological Features of Seborrheic-Like Dermatitis in HIV-Infected Adults: A Single Institutional Descriptive Cross-Sectional Study. 61
32379092 2021
22
The Effect of Volatile Oil from Chinese Mugwort Leaf on Human Demodecid Mites In Vitro. 61
33394383 2021
23
A Review of the Current Evidence Connecting Seborrheic Dermatitis and Parkinson's Disease and the Potential Role of Oral Cannabinoids. 61
33333525 2020
24
Topical crisaborole is an efficacious steroid-sparing agent for treating mild-to-moderate seborrhoeic dermatitis. 61
32452557 2020
25
Seborrheic dermatitis in COVID-19: a case report. 61
33095515 2020
26
Seborrheic dermatitis-like metastatic breast cancer. 61
32892419 2020
27
Primary health care and family physicians provide frontline care to the dermatology patients during the era of COVID-19: Recommendations and future directions. 61
33681009 2020
28
Activation studies of the β-carbonic anhydrases from Malassezia restricta with amines and amino acids. 61
32216477 2020
29
Consensus on the use of oral isotretinoin in dermatology - Brazilian Society of Dermatology. 61
33036809 2020
30
Home remedies in different pediatric dermatoses: An observational study. 61
32761779 2020
31
Dyshidrotic eczema and seborrheic dermatitis-like eczematous eruption following intravenous immunoglobulin therapy. 61
32767429 2020
32
Efficacy and Tolerability of a Shampoo Containing Broad-Spectrum Cannabidiol in the Treatment of Scalp Inflammation in Patients with Mild to Moderate Scalp Psoriasis or Seborrheic Dermatitis. 61
33313051 2020
33
Topographic Differential Diagnosis of Chronic Plaque Psoriasis: Challenges and Tricks. 61
33171581 2020
34
Vitamins A, B, C, and D: A Short Review for the Dermatologist. 61
33245705 2020
35
Evaluation of the effects of COVID-19 pandemic on hair diseases through a web-based questionnaire. 61
32594627 2020
36
COVID-19 pandemic and the skin: what should dermatologists know? 61
33341217 2020
37
Eosinophilic pustular folliculitis (EPF) in a patient with HIV infection. 61
33237446 2020
38
Malassezia species may play potential roles in the pathogenesis of meibomian gland dysfunction. 61
33254481 2020
39
Successful treatment of erythematous-squamous disorders of the external auditory canal with tacrolimus and clotrimazole in otic oil: Our experience in 25 patients. 61
33112026 2020
40
Risk Factors for Seborrhoeic Dermatitis Flares: Case-control and Case-crossover Study. 61
33047149 2020
41
Improvement of severe facial seborrheic dermatitis following low-dose isotretinoin therapy. 61
30249087 2020
42
[NEONATAL SKIN MANIFESTATION OF LANGERHANS CELL HISTIOCYTOSIS]. 61
33103391 2020
43
Seborrheic dermatitis and anti-COVID-19 masks. 61
32790897 2020
44
Dermatological Manifestations of Parkinson's Disease: Clues for Diagnosis. 61
33173642 2020
45
Cutaneous manifestations in an Italian military COVID hub. 61
33295741 2020
46
Effect of Nasal Skin Type on Skin Problems following Rhinoplasty. 61
32717761 2020
47
A Novel Virus Alters Gene Expression and Vacuolar Morphology in Malassezia Cells and Induces a TLR3-Mediated Inflammatory Immune Response. 61
32873759 2020
48
Dermatologic conditions in Down syndrome: A single-center retrospective chart review. 61
32519435 2020
49
Eyelid Disorders in Ophthalmology Practice: Results from a Large International Epidemiological Study in Eleven Countries. 61
32613590 2020
50
Separation and HPLC Characterization of Active Natural Steroids in a Standardized Extract from the Serratula coronata Herb with Antiseborrheic Dermatitis Activity. 61
32899750 2020
Sources

Variations for Seborrheic Dermatitis

About this section
Sources

Expression for Seborrheic Dermatitis

About this section
Search GEO for disease gene expression data for Seborrheic Dermatitis.
Sources

Pathways for Seborrheic Dermatitis

About this section

Pathways related to Seborrheic Dermatitis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Keratinization 65
Show member pathways
 12.12 SPRR2D SPINK5 FLG DSG1
2
Tight junction 36
11.79 CD1E CD1C CD1B CD1A
3
Amoebiasis 36
11.47 CD1E CD1C CD1B CD1A
4
Innate Lymphoid Cell Differentiation Pathways 64
11.4 CD4 CCR6 AHR
5
Dendritic Cells Developmental Lineage Pathway 64
11.13 CD4 CD207 CD1C CD1A
6
Hematopoietic cell lineage 36
11.02 CD4 CD1E CD1C CD1B CD1A
Sources

GO Terms for Seborrheic Dermatitis

About this section

Cellular components related to Seborrheic Dermatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cornified envelope GO:0001533 9.13 SPRR2D FLG DSG1
2 external side of plasma membrane GO:0009897 9.1 CD4 CD1E CD1C CD1B CD1A CCR6

Biological processes related to Seborrheic Dermatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.8 DEFB4A CD4 CD1E CD1C CD1B CD1A
2 adaptive immune response GO:0002250 9.77 CD4 CD1E CD1C CD1B CD1A
3 cornification GO:0070268 9.62 SPRR2D SPINK5 FLG DSG1
4 positive regulation of T cell mediated cytotoxicity GO:0001916 9.46 CD1E CD1C CD1B CD1A
5 antigen processing and presentation, exogenous lipid antigen via MHC class Ib GO:0048007 9.26 CD1E CD1C CD1B CD1A
6 antigen processing and presentation, endogenous lipid antigen via MHC class Ib GO:0048006 8.92 CD1E CD1C CD1B CD1A

Molecular functions related to Seborrheic Dermatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 lipopeptide binding GO:0071723 9.46 CD1E CD1C CD1B CD1A
2 carbonate dehydratase activity GO:0004089 9.26 CA5B CA13
3 exogenous lipid antigen binding GO:0030884 9.26 CD1E CD1C CD1B CD1A
4 endogenous lipid antigen binding GO:0030883 8.92 CD1E CD1C CD1B CD1A
Sources

Sources for Seborrheic Dermatitis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....